
PCI Pharma Services
Provider of outsourced services to the global pharmaceutical market.
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Growth Equity non VC | |
N/A | Acquisition | ||
N/A | Buyout | ||
* | $4.0b | Debt | |
* | N/A Valuation: $10.0b | Growth Equity non VC | |
* | N/A | N/A | Debt |
Total Funding | - |
Related Content
PCI Services is a leading Contract Development and Manufacturing Organization (CDMO) specializing in the pharmaceutical and biopharmaceutical industries. The company provides comprehensive preclinical and clinical drug development services, including highly potent processing, through its world-class facilities. PCI seamlessly transitions from clinical activities to commercial-scale manufacturing, ensuring a continuous and integrated customer experience. The company serves a global client base, operating in North America, Asia Pacific, the UK, and Europe, delivering over 200 protocols annually in more than 100 countries. PCI's business model focuses on organic growth, strategic acquisitions, and partnerships to enhance its service offerings and meet future market needs. Revenue is generated through long-term contracts with pharmaceutical and biopharmaceutical companies, providing end-to-end supply chain solutions.
Keywords: CDMO, drug development, clinical trials, commercial manufacturing, biopharmaceutical, supply chain, global service, strategic partnerships, operational excellence, highly potent processing.
Tech stack
Investments by PCI Pharma Services
Edit




